You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 16, 2025

Drug Price Trends for INDOMETHACIN ER


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for INDOMETHACIN ER

Average Pharmacy Cost for INDOMETHACIN ER

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
INDOMETHACIN ER 75 MG CAPSULE 68084-0411-11 0.17869 EACH 2025-01-22
INDOMETHACIN ER 75 MG CAPSULE 65162-0506-03 0.17869 EACH 2025-01-22
INDOMETHACIN ER 75 MG CAPSULE 65162-0506-09 0.17869 EACH 2025-01-22
INDOMETHACIN ER 75 MG CAPSULE 10702-0016-01 0.17869 EACH 2025-01-22
INDOMETHACIN ER 75 MG CAPSULE 65162-0506-06 0.17869 EACH 2025-01-22
INDOMETHACIN ER 75 MG CAPSULE 31722-0565-01 0.17869 EACH 2025-01-22
INDOMETHACIN ER 75 MG CAPSULE 31722-0565-60 0.17869 EACH 2025-01-22
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Market Analysis and Price Projections for Indomethacin ER

Market Overview

Indomethacin, a nonsteroidal anti-inflammatory drug (NSAID), is widely used to relieve pain and swelling in patients suffering from arthritis, bursitis, gout, tendonitis, and other inflammatory conditions. The market for indomethacin, particularly the extended-release (ER) formulation, is experiencing significant growth driven by several key factors.

Market Size and Growth Projections

The global indomethacin market was valued at USD 1.2 billion in 2023 and is expected to reach USD 2.1 billion by 2031, growing at a compound annual growth rate (CAGR) of 6.5% from 2024 to 2031[1].

Segmentation and Applications

The indomethacin market is segmented based on application, product type, and geography. Key applications include pain management, inflammation reduction, gout, rheumatoid arthritis, and osteoarthritis. The product types include indomethacin capsules, suppositories, oral suspension, and powder[1].

Regional Analysis

The market is geographically segmented into North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. Each region is further sub-segmented by country, providing a detailed overview of the market dynamics in each area. The Asia-Pacific region is expected to show significant growth due to the expanding pharmaceutical industry and increasing healthcare access in developing nations[4].

Market Drivers

  • Increasing Prevalence of Inflammatory Diseases: The rising incidence of gout and arthritis is a major driver for the indomethacin market. These conditions require effective NSAIDs like indomethacin for pain and inflammation management[1][4].
  • Advancements in Formulations: Continued research and the development of novel formulations that improve the safety and efficacy of indomethacin are crucial for market expansion. Improved administration methods and formulations enhance patient compliance and treatment outcomes[1].
  • Growing Healthcare Access: Increasing global awareness and access to efficient therapies for inflammatory illnesses and chronic pain are driving the demand for indomethacin[1].

Market Restraints

  • Side Effects and Safety Concerns: Despite its efficacy, indomethacin can have significant side effects, such as gastrointestinal issues and cardiovascular risks. These safety concerns can limit market growth if not adequately addressed through improved formulations and dosing strategies[4].
  • Regulatory Challenges: Strict regulatory environments and the need for compliance with various international standards can pose challenges for market players, especially new entrants[2].

Price Projections and Cost Analysis

The cost of indomethacin ER can vary based on the formulation, dosage, and geographical location.

  • Current Pricing: Patients can expect to pay around $103.44 for 30 capsules of 75mg Indomethacin ER, although prices can be reduced with coupons or discounts[5].
  • Price Trends: The prices of indomethacin ER are influenced by factors such as production costs, regulatory approvals, and market competition. As the market grows, there may be a slight increase in prices due to increased demand, but this is likely to be balanced by the introduction of generic versions and competitive pricing strategies[3].

Competitive Landscape

The indomethacin market is competitive, with several key players including Merck & Co., Teva Pharmaceuticals, Mylan, Novartis, GlaxoSmithKline, Sun Pharmaceutical, Zydus Cadila, Cipla, Lupin, and Aurobindo Pharma. These companies are focusing on organic and inorganic growth strategies such as product launches, acquisitions, and partnerships to expand their market share[1][4].

Porter’s Five Forces Analysis

  • Buyer’s Bargaining Power: Moderate to high due to the availability of generic alternatives and the sensitivity of patients to drug prices.
  • Supplier’s Bargaining Power: Moderate, as suppliers of raw materials and manufacturing services have some leverage but are also subject to competition.
  • Threat of New Entrants: Low to moderate, due to the regulatory barriers and the need for significant investment in research and development.
  • Threat of Substitutes: Moderate, as other NSAIDs and alternative treatments are available.
  • Degree of Competition: High, due to the presence of multiple established players and the ongoing competition for market share[1].

Technological and Regulatory Trends

The market is influenced by technological advancements in drug formulation and delivery systems. For instance, the development of extended-release formulations like Indomethacin ER enhances patient compliance and reduces the frequency of dosing. Regulatory trends, including stricter safety and efficacy standards, also play a crucial role in shaping the market[2][4].

Consumer Behavior Analysis

Consumer behavior is increasingly influenced by the need for effective and safe treatments for chronic pain and inflammatory conditions. Patients are more informed and seek medications with minimal side effects and improved efficacy. This trend drives the demand for advanced formulations like Indomethacin ER[4].

COVID-19 Impact

The COVID-19 pandemic has had a mixed impact on the indomethacin market. On one hand, it has highlighted the importance of efficient healthcare systems and the need for effective treatments for chronic conditions. On the other hand, it has posed challenges in terms of supply chain disruptions and delayed clinical trials. However, the overall demand for indomethacin has remained robust due to its essential role in managing inflammatory diseases[2].

Key Takeaways

  • The global indomethacin market is expected to grow significantly, driven by the increasing prevalence of inflammatory diseases and advancements in drug formulations.
  • The extended-release formulation of indomethacin is particularly popular due to its improved efficacy and patient compliance.
  • The market is competitive, with several key players focusing on organic and inorganic growth strategies.
  • Regulatory and technological trends are crucial in shaping the market dynamics.
  • Consumer behavior is increasingly focused on safe and effective treatments, driving the demand for advanced formulations.

FAQs

1. What is the expected growth rate of the indomethacin market from 2024 to 2031?

The indomethacin market is expected to grow at a CAGR of 6.5% from 2024 to 2031[1].

2. Which regions are expected to dominate the indomethacin market?

North America and the Asia-Pacific region are expected to be significant markets for indomethacin, with the latter showing high growth potential due to the expanding pharmaceutical industry[4].

3. What are the key drivers of the indomethacin market?

The key drivers include the increasing prevalence of gout and arthritis, advancements in drug formulations, and growing healthcare access in developing nations[1][4].

4. How does the competitive landscape of the indomethacin market look?

The market is highly competitive with several established players like Merck & Co., Teva Pharmaceuticals, and Novartis, among others. These companies are engaged in various growth strategies including product launches, acquisitions, and partnerships[1][4].

5. What is the current pricing for Indomethacin ER, and how is it expected to change?

The current price for 30 capsules of 75mg Indomethacin ER is around $103.44. Prices may fluctuate based on market competition, regulatory changes, and the introduction of generic versions, but overall, they are expected to remain competitive[5].

Cited Sources:

  1. Marketresearchintellect.com - Indomethacin Market Size, Share and Trends [2024-2031]
  2. Cognitivemarketresearch.com - Indomethacin Market Report 2024 (Global Edition)
  3. Drugpatentwatch.com - Drug prices and trends for INDOMETHACIN
  4. Theinsightpartners.com - Indomethacin Market Insights and Growth by 2031
  5. Singlecare.com - Indomethacin Er Coupons & Prices - SingleCare

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.